References
- Prokofyeva E, Zrenner E. Epidemiology of major eye diseases leading to blindness in Europe: A literature review. Ophthalmic Res 2012;47:171–188.
- Cheung CM, Tai ES, Kawasaki R, et al. Prevalence of and risk factors for AMD in a multiethnic Asian cohort. Arch Ophthalmol 2012;130:480–486.
- Ye H, Zhang Q, Liu X, et al. Prevalence of AMD in an elderly urban Chinese population in China: The Jiangning Eye Study. Invest Ophthalmol Vis Sci 2014;55:6374–6380.
- Hampton BM, Kovach JL, Schwartz SG, et al. Pharmacogenetics and nutritional supplementation in AMD. Clin Ophthalmol 2015;9:873–876.
- Kourlas H, Abrams P. Ranibizumab for the treatment of neovascular age-related macular degeneration: A review. Clin Ther 2007;29:1850–1861.
- Bloch SB, Larsen M, Munch IC. Incidence of legal blindness from AMD in Denmark: Year 2000 to 2010. Am J Ophthalmol 2012;153:209–213.
- Cruz-Gonzalez F, Cabrillo-Estévez L, López-Valverde G, et al. Predictive value of VEGF A and VEGFR2 polymorphisms in the response to intravitreal ranibizumab treatment for wet AMD. Graefes Arch Clin Exp Ophthalmol 2014;252:469–475.
- Galan A, Ferlin A, Caretti L, et al. Association of AMD with polymorphisms in vascular endothelial growth factor and its receptor. Ophthalmology 2010;117:1769–1774.
- Owen, LA, Morrison MA, Ahn J, et al. FLT1 genetic variation predisposes to neovascular AMD in ethnically diverse populations and alters systemic FLT1 expression. Invest Ophthalmol Vis Sci 2014;55:3543–3554.
- Patel N, Adewoyin T, Chong NV. AMD: A perspective on genetic studies. Eye (Lond) 2008;22:768–776.
- Danis RP, Domalpally A, Chew EY, et al. Methods and reproducibility of grading optimized digital color fundus photographs in the Age-Related Eye Disease Study 2 (AREDS2 Report Number 2). Invest Ophthalmol Vis Sci 2013;54:4548–4554.
- Lu F, Shi Y, Qu C, et al. A genetic variant in the SKIV2L gene is significantly associated with AMD in a Han Chinese population. Invest Ophthalmol Vis Sci 2013;54:2911–2917.
- Koh SP, Yip SP, Lee KK, et al. Genetic association between germline JAK2 polymorphisms and myeloproliferative neoplasms in Hong Kong Chinese populatio147n: A case-control study. BMC Genet 2014;15:.
- Liu ZH, Ding YL, Xiu LC, et al. A meta-analysis of the association between TNF-alpha -308G: A polymorphism and type 2 diabetes mellitus in Han Chinese population. PLoS One 2013;8(3):e59421.
- Lambrechts D, Claes B, Delmar P, et al. VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: An analysis of data from the AVITA and AVOREN randomised trials. Lancet Oncol 2012;7:724–733.
- Hiratsuka S, Maru Y, Okada A, et al. Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. Cancer Res 2001;61:1207–1213.
- Ohno-Matsui K, Yoshida T, Uetama T, et al. Vascular endothelial growth factor upregulates pigment epithelium-derived factor expression via VEGFR-1 in human retinal pigment epithelial cells. Biochem Biophys Res Commun 2003;303:962–967.
- Luttun A, Tjwa M, Carmeliet P. Placental growth factor (PlGF) and its receptor Flt-1 (VEGFR-1): Novel therapeutic targets for angiogenic disorders. Ann N Y Acad Sci 2002;979:80–93.
- Shibuya M, Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 2006;312:549–560.
- Rakic JM, Lambert V, Devy L, et al. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci 2003;44:3186–3193.
- Francis PJ. The influence of genetics on response to treatment with ranibizumab (Lucentis) for AMD: The Lucentis Genotype Study (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 2011;109:115–156.
- Zhao H, Nettleton D, Soller M, et al. Evaluation of linkage disequilibrium measures between multi-allelic markers as predictors of linkage disequilibrium between markers and QTL. Genet Res 2005;86:77–87.